​

Corcept Therapeutics (CORT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CORT Stock Forecast

Corcept Therapeutics stock forecast is as follows: an average price target of $68.00 (represents a 32.30% upside from CORT’s last price of $51.40) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

CORT Price Target

The average price target for Corcept Therapeutics (CORT) is $68.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $80.00 to $38.00. This represents a potential 32.30% upside from CORT's last price of $51.40.

CORT Analyst Ratings

Buy

According to 6 Wall Street analysts, Corcept Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CORT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Corcept Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 18, 2024Swayampakula RamakanthH.C. Wainwright$80.00$47.1769.60%55.64%
Sep 30, 2024Joon LeeTruist Financial$76.00$43.9373.00%47.86%
Aug 15, 2024Edward NashCanaccord Genuity$78.00$34.71124.72%51.75%
Jul 30, 2024David AmsellemPiper Sandler$38.00$36.125.20%-26.07%
Jul 30, 2024Swayampakula RamakanthH.C. Wainwright$45.00$36.5323.19%-12.45%
Jun 12, 2024Edward NashCanaccord Genuity$38.00$32.7915.89%-26.07%
Jun 10, 2024David AmsellemPiper Sandler$35.00$31.5111.08%-31.91%
Jun 04, 2024Joon LeeTruist Financial$65.00$31.59105.76%26.46%
May 02, 2024Swayampakula RamakanthH.C. Wainwright$40.00$23.8867.50%-22.18%
Dec 09, 2022H.C. Wainwright$30.00$23.0130.38%-41.63%
Aug 04, 2022H.C. Wainwright$33.00$28.7114.94%-35.80%

The latest Corcept Therapeutics stock forecast, released on Oct 18, 2024 by Swayampakula Ramakanth from H.C. Wainwright, set a price target of $80.00, which represents a 69.60% increase from the stock price at the time of the forecast ($47.17), and a 55.64% increase from CORT last price ($51.40).

Corcept Therapeutics Price Target by Period

1M3M12M
# Anlaysts-29
Avg Price Target-$78.00$55.00
Last Closing Price$51.40$51.40$51.40
Upside/Downside-100.00%51.75%7.00%

In the current month, the average price target of Corcept Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Corcept Therapeutics's last price of $51.40. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 18, 2024Sandler O'NeillBuyBuyHold
Oct 18, 2024Sandler O'NeilUnderperformUnderperformHold
Oct 18, 2024H.C. WainwrightBuyBuyHold
Sep 25, 2024Canaccord GenuityBuyBuyHold
Sep 18, 2024Sandler O'NeilUnderperformUnderperformHold
Sep 18, 2024Sandler O'NeillBuyBuyHold
Sep 18, 2024Piper SandlerOverweightOverweightHold
Aug 15, 2024Canaccord GenuityBuyBuyHold
Jul 30, 2024Truist FinancialBuyBuyHold
Jul 30, 2024Sandler O'NeillUnderperformUnderperformHold
Jul 30, 2024Piper SandlerOverweightOverweightHold
Jul 30, 2024H.C. WainwrightBuyBuyHold
Jul 01, 2024Piper SandlerOverweightOverweightHold
Jun 17, 2024Truist FinancialBuyBuyHold
Jun 17, 2024H.C. WainwrightUnderperformUnderperformHold
Jun 12, 2024Canaccord GenuityBuyBuyHold
Jun 10, 2024Piper SandlerOverweightOverweightHold
May 29, 2024H.C. WainwrightBuyBuyHold
May 02, 2024Truist FinancialBuyBuyHold
May 02, 2024H.C. WainwrightUnderperformUnderperformHold
May 02, 2024H.C. WainwrightBuyBuyHold
Jul 27, 2022JefferiesBuyUpgrade

Corcept Therapeutics's last stock rating was published by Sandler O'Neill on Oct 18, 2024. The company gave CORT a "Buy" rating, the same as its previous rate.

Corcept Therapeutics Financial Forecast

Corcept Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue--------$135.41M$123.60M$117.72M$105.65M$103.06M$101.73M$103.39M$93.69M$98.82M$96.13M$91.59M$79.44M$85.73M$86.33M$88.56M$93.25M$87.89M$81.50M$72.26M$64.83M$57.66M$27.60M
Avg Forecast$214.23M$205.38M$196.57M$189.80M$198.02M$171.97M$155.14M$141.19M$129.27M$119.71M$109.60M$104.89M$105.08M$107.57M$101.00M$98.88M$100.57M$97.19M$86.84M$91.81M$90.36M$90.87M$90.13M$87.00M$87.67M$78.00M$70.88M$69.29M$65.90M$20.70M
High Forecast$228.43M$218.99M$209.61M$200.64M$209.69M$172.38M$165.42M$141.19M$137.84M$120.13M$116.87M$111.84M$112.05M$107.57M$101.00M$98.88M$100.57M$97.19M$86.84M$91.81M$90.36M$90.87M$90.13M$87.00M$87.67M$78.00M$70.88M$69.29M$79.08M$24.84M
Low Forecast$199.68M$191.43M$183.23M$176.60M$190.67M$171.55M$144.60M$141.19M$120.49M$118.93M$102.16M$97.76M$97.94M$107.57M$101.00M$98.88M$100.57M$97.19M$86.84M$91.81M$90.36M$90.87M$90.13M$87.00M$87.67M$78.00M$70.88M$69.29M$52.72M$16.56M
# Analysts1114421116334444333331599881216198
Surprise %--------1.05%1.03%1.07%1.01%0.98%0.95%1.02%0.95%0.98%0.99%1.05%0.87%0.95%0.95%0.98%1.07%1.00%1.04%1.02%0.94%0.88%1.33%

Corcept Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $141.19M, with a low forecast of $141.19M, and a high forecast of $141.19M. CORT's average Quarter revenue forecast represents a 4.27% increase compared to the company's last Quarter revenue of $135.41M (Dec 23).

Corcept Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1114421116334444333331599881216198
EBITDA--------$32.30M$31.18M$29.58M$14.85M$22.50M$32.69M$31.43M$27.57M$37.60M$37.15M$32.92M$20.93M$31.67M$26.53M$37.79M$41.26M$38.47M$36.27M$27.52M$21.66M$21.63M$4.75M
Avg Forecast$67.90M$65.10M$62.31M$60.16M$62.76M$54.51M$49.17M$39.15M$40.97M$37.94M$34.74M$35.59M$33.84M$33.87M$31.80M$32.35M$31.66M$30.60M$27.34M$23.61M$28.45M$28.61M$28.38M$34.36M$27.60M$24.56M$22.31M$24.89M$24.00M$3.17M
High Forecast$72.40M$69.41M$66.44M$63.59M$66.46M$54.64M$52.43M$46.98M$43.69M$38.08M$37.04M$42.71M$40.61M$33.87M$31.80M$38.82M$31.66M$30.60M$27.34M$28.33M$28.45M$28.61M$28.38M$41.23M$27.60M$24.56M$22.31M$29.87M$28.80M$3.80M
Low Forecast$63.29M$60.67M$58.08M$55.98M$60.44M$54.38M$45.83M$31.32M$38.19M$37.70M$32.38M$28.47M$27.08M$33.87M$31.80M$25.88M$31.66M$30.60M$27.34M$18.89M$28.45M$28.61M$28.38M$27.49M$27.60M$24.56M$22.31M$19.91M$19.20M$2.53M
Surprise %--------0.79%0.82%0.85%0.42%0.66%0.97%0.99%0.85%1.19%1.21%1.20%0.89%1.11%0.93%1.33%1.20%1.39%1.48%1.23%0.87%0.90%1.50%

1 analysts predict CORT's average Quarter EBITDA for Mar 24 to be $39.15M, with a high of $46.98M and a low of $31.32M. This is 21.20% upper than Corcept Therapeutics's previous annual EBITDA (Dec 23) of $32.30M.

Corcept Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1114421116334444333331599881216198
Net Income--------$31.36M$31.17M$27.36M$15.88M$16.60M$34.61M$27.41M$22.80M$32.05M$30.47M$26.52M$23.46M$25.99M$21.63M$28.33M$30.07M$29.38M$26.34M$20.19M$18.27M$17.46M$4.39M
Avg Forecast$59.70M$52.31M$46.91M$43.50M$42.76M$32.06M$26.16M$32.18M$29.35M$24.83M$17.06M$29.26M$28.85M$26.03M$26.33M$26.60M$25.03M$23.92M$18.36M$26.82M$18.36M$23.36M$24.75M$25.97M$29.11M$22.06M$20.30M$22.12M$19.64M$2.93M
High Forecast$64.85M$56.82M$50.95M$57.57M$50.85M$32.51M$28.41M$38.62M$31.70M$29.34M$18.53M$35.11M$34.62M$26.03M$26.33M$31.92M$25.03M$23.92M$18.36M$32.18M$18.36M$23.36M$24.75M$31.16M$29.11M$22.06M$20.30M$26.55M$23.57M$3.51M
Low Forecast$54.43M$47.69M$42.77M$31.98M$32.36M$31.61M$23.85M$25.75M$24.66M$18.06M$15.55M$23.40M$23.08M$26.03M$26.33M$21.28M$25.03M$23.92M$18.36M$21.45M$18.36M$23.36M$24.75M$20.77M$29.11M$22.06M$20.30M$17.70M$15.71M$2.34M
Surprise %--------1.07%1.26%1.60%0.54%0.58%1.33%1.04%0.86%1.28%1.27%1.44%0.88%1.42%0.93%1.14%1.16%1.01%1.19%0.99%0.83%0.89%1.50%

Corcept Therapeutics's average Quarter net income forecast for Mar 24 is $32.18M, with a range of $25.75M to $38.62M. CORT's average Quarter net income forecast represents a 2.64% increase compared to the company's last Quarter net income of $31.36M (Dec 23).

Corcept Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1114421116334444333331599881216198
SG&A--------$47.15M$45.26M$43.28M$48.56M$42.32M$35.16M$37.81M$37.55M$32.28M$30.53M$30.03M$29.51M$25.70M$26.52M$25.57M$27.54M$27.13M$24.25M$24.59M$24.39M$18.44M$15.04M
Avg Forecast$73.77M$70.72M$67.69M$65.36M$68.19M$59.22M$53.42M$53.01M$44.51M$41.22M$37.74M$48.19M$29.06M$37.04M$34.78M$43.81M$34.63M$33.47M$29.90M$33.72M$31.12M$31.29M$31.04M$23.78M$30.19M$26.86M$24.41M$29.52M$20.75M$10.02M
High Forecast$78.66M$75.41M$72.18M$69.09M$72.21M$59.36M$56.96M$63.61M$47.46M$41.37M$40.24M$57.83M$34.87M$37.04M$34.78M$52.57M$34.63M$33.47M$29.90M$40.47M$31.12M$31.29M$31.04M$28.54M$30.19M$26.86M$24.41M$35.43M$24.89M$12.03M
Low Forecast$68.76M$65.92M$63.09M$60.81M$65.66M$59.07M$49.79M$42.41M$41.49M$40.95M$35.18M$38.55M$23.25M$37.04M$34.78M$35.05M$34.63M$33.47M$29.90M$26.98M$31.12M$31.29M$31.04M$19.02M$30.19M$26.86M$24.41M$23.62M$16.60M$8.02M
Surprise %--------1.06%1.10%1.15%1.01%1.46%0.95%1.09%0.86%0.93%0.91%1.00%0.88%0.83%0.85%0.82%1.16%0.90%0.90%1.01%0.83%0.89%1.50%

Corcept Therapeutics's average Quarter SG&A projection for Mar 24 is $53.01M, based on 1 Wall Street analysts, with a range of $42.41M to $63.61M. The forecast indicates a 12.42% rise compared to CORT last annual SG&A of $47.15M (Dec 23).

Corcept Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1114421116334444333331599881216198
EPS--------$0.29$0.31$0.27$0.15$0.15$0.32$0.26$0.22$0.28$0.26$0.23$0.20$0.22$0.19$0.25$0.26$0.26$0.23$0.18$0.16$0.15$0.04
Avg Forecast$0.53$0.46$0.41$0.38$0.38$0.28$0.23$0.22$0.26$0.22$0.15$0.20$0.24$0.23$0.24$0.23$0.23$0.21$0.17$0.22$0.17$0.21$0.22$0.22$0.26$0.20$0.18$0.19$0.18$0.02
High Forecast$0.57$0.50$0.45$0.51$0.45$0.29$0.25$0.24$0.28$0.26$0.16$0.22$0.26$0.23$0.24$0.23$0.23$0.21$0.17$0.22$0.17$0.21$0.22$0.22$0.26$0.20$0.18$0.19$0.22$0.02
Low Forecast$0.48$0.42$0.38$0.28$0.28$0.28$0.21$0.20$0.22$0.16$0.14$0.18$0.22$0.23$0.24$0.23$0.23$0.21$0.17$0.22$0.17$0.21$0.22$0.22$0.26$0.20$0.18$0.19$0.14$0.02
Surprise %--------1.12%1.42%1.80%0.76%0.63%1.37%1.10%0.95%1.24%1.21%1.39%0.92%1.33%0.90%1.12%1.17%0.99%1.16%0.99%0.84%0.83%2.00%

According to 1 Wall Street analysts, Corcept Therapeutics's projected average Quarter EPS for Mar 24 is $0.22, with a low estimate of $0.20 and a high estimate of $0.24. This represents a -24.14% decrease compared to CORT previous annual EPS of $0.29 (Dec 23).

Corcept Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
SNSESensei Biotherapeutics$0.48$5.501045.83%Buy
KROSKeros Therapeutics$18.00$102.00466.67%Buy
NXTCNextCure$0.90$3.00233.33%Buy
ANABAnaptysBio$15.99$49.83211.63%Buy
NUVBNuvation Bio$2.81$7.00149.11%Buy
MLYSMineralys Therapeutics$12.35$30.00142.91%Buy
ERASErasca$2.63$6.00128.14%Buy
IDYAIDEAYA Biosciences$26.33$53.33102.54%Buy
RAREUltragenyx Pharmaceutical$44.95$90.00100.22%Buy
CYTKCytokinetics$47.78$90.0088.36%Buy
DYNDyne Therapeutics$26.16$49.0087.31%Buy
EWTXEdgewise Therapeutics$30.17$46.2553.30%Buy
MGTXMeiraGTx$6.40$9.0040.63%Buy
AGIOAgios Pharmaceuticals$41.96$53.5027.50%Buy
CORTCorcept Therapeutics$55.14$68.0023.32%Buy
INSMInsmed$73.85$87.5018.48%Buy
HALOHalozyme Therapeutics$48.60$52.007.00%Buy

CORT Forecast FAQ

Is Corcept Therapeutics a good buy?

Yes, according to 6 Wall Street analysts, Corcept Therapeutics (CORT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of CORT's total ratings.

What is CORT's price target?

Corcept Therapeutics (CORT) average price target is $68 with a range of $38 to $80, implying a 32.30% from its last price of $51.4. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Corcept Therapeutics stock go up soon?

According to Wall Street analysts' prediction for CORT stock, the company can go up by 32.30% (from the last price of $51.4 to the average price target of $68), up by 55.64% based on the highest stock price target, and down by -26.07% based on the lowest stock price target.

Can Corcept Therapeutics stock reach $80?

CORT's average twelve months analyst stock price target of $68 does not support the claim that Corcept Therapeutics can reach $80 in the near future.

What are Corcept Therapeutics's analysts' financial forecasts?

Corcept Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $666.32M (high $688.68M, low $648.02M), average EBITDA is $205.59M (high $220.51M, low $191.96M), average net income is $133.16M (high $150.39M, low $113.56M), average SG&A $233.83M (high $252.14M, low $216.93M), and average EPS is $1.11 (high $1.22, low $0.973). CORT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $805.98M (high $857.66M, low $750.94M), average EBITDA is $255.46M (high $271.85M, low $238.02M), average net income is $202.43M (high $230.2M, low $176.88M), average SG&A $277.54M (high $295.34M, low $258.59M), and average EPS is $1.78 (high $2.02, low $1.56).

Did the CORT's actual financial results beat the analysts' financial forecasts?

Based on Corcept Therapeutics's last annual report (Dec 2023), the company's revenue was $482.38M, beating the average analysts forecast of $463.47M by 4.08%. Apple's EBITDA was $109.64M, missing the average prediction of $149.24M by -26.53%. The company's net income was $106.14M, beating the average estimation of $100.5M by 5.62%. Apple's SG&A was $184.26M, beating the average forecast of $171.67M by 7.34%. Lastly, the company's EPS was $1.02, beating the average prediction of $0.825 by 23.63%. In terms of the last quarterly report (Dec 2023), Corcept Therapeutics's revenue was $135.4M, beating the average analysts' forecast of $129.27M by 4.75%. The company's EBITDA was $32.3M, missing the average prediction of $40.97M by -21.17%. Corcept Therapeutics's net income was $31.36M, beating the average estimation of $29.35M by 6.82%. The company's SG&A was $47.15M, beating the average forecast of $44.51M by 5.93%. Lastly, the company's EPS was $0.29, beating the average prediction of $0.258 by 12.36%